330 related articles for article (PubMed ID: 16634035)
1. Natalizumab effects on immune cell responses in multiple sclerosis.
Niino M; Bodner C; Simard ML; Alatab S; Gano D; Kim HJ; Trigueiro M; Racicot D; Guérette C; Antel JP; Fournier A; Grand'Maison F; Bar-Or A
Ann Neurol; 2006 May; 59(5):748-54. PubMed ID: 16634035
[TBL] [Abstract][Full Text] [Related]
2. Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.
Wipfler P; Oppermann K; Pilz G; Afazel S; Haschke-Becher E; Harrer A; Huemer M; Kunz A; Golaszewski S; Staffen W; Ladurner G; Kraus J
Mult Scler; 2011 Jan; 17(1):16-23. PubMed ID: 20937631
[TBL] [Abstract][Full Text] [Related]
3. Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells.
Putzki N; Baranwal MK; Tettenborn B; Limmroth V; Kreuzfelder E
Eur Neurol; 2010; 63(5):311-7. PubMed ID: 20453514
[TBL] [Abstract][Full Text] [Related]
4. Immune surveillance in multiple sclerosis patients treated with natalizumab.
Stüve O; Marra CM; Jerome KR; Cook L; Cravens PD; Cepok S; Frohman EM; Phillips JT; Arendt G; Hemmer B; Monson NL; Racke MK
Ann Neurol; 2006 May; 59(5):743-7. PubMed ID: 16634029
[TBL] [Abstract][Full Text] [Related]
5. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis.
Krumbholz M; Meinl I; Kümpfel T; Hohlfeld R; Meinl E
Neurology; 2008 Oct; 71(17):1350-4. PubMed ID: 18936427
[TBL] [Abstract][Full Text] [Related]
6. Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells.
Harrer A; Wipfler P; Einhaeupl M; Pilz G; Oppermann K; Hitzl W; Afazel S; Haschke-Becher E; Strasser P; Trinka E; Kraus J
J Neuroimmunol; 2011 May; 234(1-2):148-54. PubMed ID: 21450349
[TBL] [Abstract][Full Text] [Related]
7. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.
Calabresi PA; Giovannoni G; Confavreux C; Galetta SL; Havrdova E; Hutchinson M; Kappos L; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Rudick RA; Stuart WH; Lublin FD; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA;
Neurology; 2007 Oct; 69(14):1391-403. PubMed ID: 17761550
[TBL] [Abstract][Full Text] [Related]
8. Immunotoxicity profile of natalizumab.
Wehner NG; Gasper C; Shopp G; Nelson J; Draper K; Parker S; Clarke J
J Immunotoxicol; 2009 Jun; 6(2):115-29. PubMed ID: 19589098
[TBL] [Abstract][Full Text] [Related]
9. Molecular evidence of transient therapeutic effectiveness of natalizumab despite high-titre neutralizing antibodies.
Pilz G; Harrer A; Oppermann K; Wipfler P; Golaszewski S; Afazel S; Haschke-Becher E; Trinka E; Kraus J
Mult Scler; 2012 Apr; 18(4):506-9. PubMed ID: 21965415
[TBL] [Abstract][Full Text] [Related]
10. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
Stüve O; Marra CM; Bar-Or A; Niino M; Cravens PD; Cepok S; Frohman EM; Phillips JT; Arendt G; Jerome KR; Cook L; Grand'Maison F; Hemmer B; Monson NL; Racke MK
Arch Neurol; 2006 Oct; 63(10):1383-7. PubMed ID: 17030653
[TBL] [Abstract][Full Text] [Related]
11. CD49d expression as a promising biomarker to monitor natalizumab efficacy.
Defer G; Mariotte D; Derache N; Toutirais O; Legros H; Cauquelin B; Le Mauff B
J Neurol Sci; 2012 Mar; 314(1-2):138-42. PubMed ID: 22050952
[TBL] [Abstract][Full Text] [Related]
12. Natalizumab (Tysabri) treatment for relapsing multiple sclerosis.
Johnson KP
Neurologist; 2007 Jul; 13(4):182-7. PubMed ID: 17622909
[TBL] [Abstract][Full Text] [Related]
13. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
Rudick RA; Sandrock A
Expert Rev Neurother; 2004 Jul; 4(4):571-80. PubMed ID: 15853576
[TBL] [Abstract][Full Text] [Related]
14. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale.
Rice GP; Hartung HP; Calabresi PA
Neurology; 2005 Apr; 64(8):1336-42. PubMed ID: 15851719
[TBL] [Abstract][Full Text] [Related]
15. Natalizumab treatment reduces endothelial activity in MS patients.
Millonig A; Hegen H; Di Pauli F; Ehling R; Gneiss C; Hoelzl M; Künz B; Lutterotti A; Rudzki D; Berger T; Reindl M; Deisenhammer F
J Neuroimmunol; 2010 Oct; 227(1-2):190-4. PubMed ID: 20739072
[TBL] [Abstract][Full Text] [Related]
16. Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients.
Skarica M; Eckstein C; Whartenby KA; Calabresi PA
J Neuroimmunol; 2011 Jun; 235(1-2):70-6. PubMed ID: 21550672
[TBL] [Abstract][Full Text] [Related]
17. Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients.
Lindberg RL; Achtnichts L; Hoffmann F; Kuhle J; Kappos L
J Neuroimmunol; 2008 Feb; 194(1-2):153-64. PubMed ID: 18178259
[TBL] [Abstract][Full Text] [Related]
18. Memory and naïve B-cell subsets in patients with multiple sclerosis.
Niino M; Hirotani M; Miyazaki Y; Sasaki H
Neurosci Lett; 2009 Oct; 464(1):74-8. PubMed ID: 19666086
[TBL] [Abstract][Full Text] [Related]
19. Natalizumab: targeting alpha4-integrins in multiple sclerosis.
Engelhardt B; Kappos L
Neurodegener Dis; 2008; 5(1):16-22. PubMed ID: 18075270
[TBL] [Abstract][Full Text] [Related]
20. [New drugs; natalizumab].
van Bronswijk H; Dubois EA; van Gerven JM; Cohen AF
Ned Tijdschr Geneeskd; 2008 Mar; 152(9):499-500. PubMed ID: 18389881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
